LAUSR

N6‐methyladenosine (m6A) is one of the most abundant modifications determining the fate of RNA. Currently, m6A modification is tightly connected with tumorigenesis and presents novel promise in clinical applications. Regulated cell death (RCD) is a programmed mechanism that plays a complicated role in malignant transition. Regarding the main forms of RCD, aberrant levels of m6A modification have been detected during the progression of apoptosis, autophagy, ferroptosis, necroptosis, and pyroptosis in several diseases. However, few reviews have elucidated the correlation between m6A‐modified RCD and carcinogenesis. In this review, we summarize the regulators of m6A methylation and their functions in carcinogenesis through an overview of m6A‐modified RCD. Additionally, we assume the potential role of m6A modification regulators as novel biomarkers for chemotherapies and precision medicine. Furthermore, we review the controversies and conflicts in m6A explorations and predict future orientations of m6A‐modified RCD for clinical applications.